Hartland,

It is my understanding that the 3+3 dose escalation design would put us at 12 patients enrolled right now. However, it is also my understanding that these 12 patients are spread across the various study sites and does not mean that each individual study site has its own 12 patients. It's not just about safety, it is also about efficacy. They keep increasing the dose escalation until they reach the maximally tolerated dose. Hopefully, they start to achieve efficacy well before reaching the maximally tolerated dose. As to how long.....I think Zenith offered goals in their Q2 update of obtaining pharmacokinetic and safety data in H2 2016 and of reaching proof of concept in H1 2017 for the ZEN-3694 single agent trial. But these were early timelines that were offered near the beginning of dosing. And pretty soon, hopefully in H2 2016 or Q1 2017 they will begin the ZEN-3694 w/ enzalutamide combo therapy trial. We will have a better idea of the timelines of these Phase 1 trials when Zenith offers their next corporate update or AGM. Hopefully one of these happens soon......

BearDownAZ